Summit Therapeutics Inc.

SMMTNASDAQHealthcare● Active

$14.43

$-0.34(-2.29%)

Market Cap$11.2B

P/E Ratio—

52W High$30.98

52W Low$13.83

Avg Volume4.1M

Open$15.23

Beta-1.31

Overview

Summit Therapeutics Inc. (SMMT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SMMT · free cash flow · updated Jun 8, 2026

Core FCF metrics

SMMT · FCF · TTM · margin & CAGR

Free cash flow was −$240.2M for FY2025 (fiscal year ending 2025-12-31), down 111.3% year-over-year

FY2025 Free Cash Flow−$240.2M▼ -111.3% YoY

Trailing 12M (TTM)−$286.9Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SMMT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$239.7M(0M)−$240.2M▼ 111.3%—

FY2024−$113.6M(0M)−$113.7M▼ 86.8%—

FY2023−$60.7M(0M)−$60.8M▼ 76.8%—

FY2022−$33.9M(1M)−$34.4M▲ +36.3%—

FY2021−$53.8M(0M)−$54.0M▼ 51.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SMMT · P/FCF · FCF yield · FCF per share

Summit Therapeutics Inc. (SMMT) reported negative free cash flow of −$0.24B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

SMMT · cash flow statement · operating / investing / financing

For FY2025, Summit Therapeutics Inc. generated −$239.7M in operating cash flow and spent 0M in capital expenditures, yielding −$240.2M in free cash flow.

Operating Activities

−$239.7M

Cash from core business operations

2025-12-31

Investing Activities

−$129.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$458.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$239.7M) − |CapEx| (0M) = FCF (−$240.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SMMT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Summit Therapeutics Inc.YOU

SMMT

−$240.2M-111.3%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Summit Therapeutics Inc. (SMMT) reported free cash flow of −$240.2M for FY2025 (fiscal year ending 2025-12-31), down 111.3% year-over-year.

Based on available data, Summit Therapeutics Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $15.1M in FY2017.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SMMT free cash flow · 8 questions

Summit Therapeutics Inc. free cash flow was −$240.2M for FY2025, down 111.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$286.9M.

SMMT free cash flowSMMT FCFSMMT FCF 2025SMMT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Summit Therapeutics Inc. · Summit Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026